Business
Immunome Reports First Quarter 2026 Financial Results and Provides Business Update
BOTHELL, Wash., May 12, 2026--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the quarter ended March 31, 2026, and provided a business update.
About this update from Immunome, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":334,"url":"https://media.zenfs.com/en/business-wire.com/dfffe9f0e7271690fac98d382bd672f8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ZcH6HVhG.9o65wr2oDDs1g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY2ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/dfffe9f0e7271690fac98d382bd672f8","width":480,"height":334},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/qXOE4oF9XPjBbE2D.DiO5A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTQ0NTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/dfffe9f0e7271690fac98d382bd672f8","width":480,"height":334}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"New Drug Application (NDA) submitted to the U.S. Food and Drug Administration (FDA) in April 2026 seeking approval of varegacestat for the treatment of adults with desmoid tumors","length":178,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Detailed Phase 3 RINGSIDE data selected for oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting","length":133,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Phase 1 study ongoing for IM-1021, with initial lymphoma data expected in 2026","length":78,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Investigational New Drug (IND) clearance received in April 2026 for IM-1617, a potential first-in-class solid tumor antibody-drug conjugate (ADC)","length":145,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":534,"olType":false},{"type":"text","content":"BOTHELL, Wash., May 12, 2026--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the quarter ended March 31, 2026, and provided a business update.","length":287,"tagName":"p"},{"type":"text","content":""This quarter reflects the progress we are making in building Immunome into a multi-program targeted oncology company," said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Immunome. "The NDA submission for varegacestat is an important milestone that reflects our commitment to improving the lives of patients with des...